Search terms
Results 1 - 3 of 3 - ordered by :

Prof. Zannad points out that, “Rivaroxaban is approved at higher doses to treat conditions such as atrial fibrillation (AF) and venous thromboembolism, but in COMMANDER HF, patients were ...

Date : 28/08/2018

Professor Deepak L. Bhatt (Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA) describes the rationale for the study, which is the largest trial in type 2 ...

Date : 02/09/2019

ESC guidelines recommend a short period of triple therapy (oral anticoagulant, aspirin, clopidogrel) followed by a period of dual therapy (oral anticoagulant plus aspirin or clopidogrel) in atrial ...

Date : 03/09/2019